Stockreport

Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer

Altimmune, Inc.  (ALT) 
NASDAQ:AMEX Investor Relations: altimmune.com/investors
PDF Preclinical study shows systemic activity of ALT-702 following local administration Altimmune granted U.S. patent providing broad coverage of platform technology GAITH [Read more]